The novel immune checkpoint inhibitors harness the ability of the immune system to recognize and destroy cancerous cells.
Global Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028 Report `Highlights:
- Global Breast Cancer Antibodies Market Opportunity: > USD 15 Billion
- Breast Cancer Antibodies Clinical Trials Insight: > 150 Drugs In Trials
- Breast Cancer Biomarkers Sourced During Clinical Trials
- Breast Cancer Biomarkers Insight By Antibodies Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Antibody
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report: https://www.kuickresearch.com/ccformF.php?t=1646994975
The novel immune checkpoint inhibitors harness the ability of the immune system to recognize and destroy cancerous cells. The introduction of immune checkpoint inhibitors has shown clinical success in wide range of malignancies such as melanoma, lung, and others. However, the immune checkpoint inhibitor therapy in breast cancer is confined to certain subsets of patients. Given the heterogeneity of breast cancer, it is of utmost need to identify biomarkers which can identify the patients that will gain benefit from immune checkpoint inhibitor therapy.
Biomarkers are increasingly being utilized for its role in cancer diagnosis and management. Within breast cancer, the effort in biomarker discovery has led to characterization and development of several prognostic and predictive biomarkers including multigene signatures. These have been developed by advances in technologies and approaches including next generation sequencing, mass spectrometry, circulating tumor cells, and cell free DNA. The identification and characterization of biomarkers in breast cancer enabled the application of targeted antibody therapeutics to specific molecular group of patients which are likely to gain benefit.
In recent times, research has been more inclined towards the development of biomarkers. Currently, more than 200 clinical trials are ongoing which are evaluating novel biomarkers. A recent study demonstrated that the biomarker, major histocompatibility complex-II has the potential to predict immunotherapy benefit with two subtypes of breast cancer including early-stage, triple-negative breast cancer (TNBC) and high-risk, estrogen receptor-positive breast cancer (HR) when expressed on breast cancer cells. In coming years, researchers will develop a clinically standardized test to verify how stable the marker is over a long period of time and how consistent the staining is. The other biomarkers which are under evaluation include tumor mutational burden, CD274 gene, tumor infiltration lymphocytes, BRCA1/2 gene, and others.
The coming years is expected to witness rapid growth rates in the breast cancer biomarker market which is mainly due to rising investments by pharmaceutical giants in developing novel immunotherapeutic approaches for breast cancer management. Several immune checkpoint inhibitors are currently ongoing clinical trials in breast cancer treatment which are expected to enter the market during the forthcoming years. For instance, researchers are validating the combination of camrelizumab and nab-paclitaxel in advanced TNBC patients. Camrelizumab is a novel PD-1 immune checkpoint inhibitor developed by Jiangsu Hengrui Medicine. The new product launches during the forthcoming years will also surge the demand of biomarkers in the market.
As per our report findings, the global breast cancer biomarker market will witness exponential growth in coming years. Certain factors that are driving the market growth include the increased incidence of breast cancer globally, and higher acceptance of treatments for cancer in the developing regions, the paradigm shift in healthcare, from disease diagnosis to risk assessment or early diagnosis, and increasing usage of biomarkers in drug development. Moreover, huge investment by major key players in the market and large number of ongoing clinical trials is other driving factors in the market. Apart from this, researchers are currently employing artificial intelligence, machine learning, and deep learning to address the challenges of cancer biomarker discovery which will further drive the growth of the market during forthcoming years.
This report on global breast cancer biomarkers market report provides holistic understanding of the market along with market sizing, forecast, drivers, challenges, and competitive landscape. Our report provides comprehensive analysis on the approved biomarkers for breast cancer immune checkpoint inhibitors. Apart from this, in-depth analysis on the ongoing clinical trials in biomarkers associated with immune checkpoint inhibitor therapy by various phases and therapeutic indications is also mentioned in the report. The major companies mentioned in the report are Amgen, Roche, Pfizer, Gilead Sciences, GlaxoSmthKline, and others.
Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366